Nkarta announced that Nadir Mahmood has resigned his position as chief financial and business officer to serve as the chief executive officer of a private biotechnology company. Mahmood will remain with Nkarta until June 30 to ensure a transition. Nkarta remains on track to announce updated results from its ongoing clinical trial of NKX101 in the second quarter of 2023. Nkarta has initiated an external search for its next chief financial officer.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NKTX:
- Nkarta Announces Departure of Chief Financial & Business Officer
- Nkarta selloff brings buying opportunity, says H.C. Wainwright
- Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
- Nkarta reports Q4 EPS (67c), consensus (64c)
- Nkarta to Participate at Upcoming Investor Conferences